There are about 25435 clinical studies being (or have been) conducted in United Kingdom. The country of the clinical trial is determined by the location of where the clinical research is being studied. Most studies are often held in multiple locations & countries.
This multicentre, parallel group, block randomised clinical trial aims to investigate the post booster antibody response in UK infants given a reduced priming schedule of meningococcal serogroup B vaccine and 13 valent pneumococcal conjugate vaccine. It will provide information about how best to include the meningococcal B vaccine (likely to be introduced late 2015) into the routine immunisation schedule. The UK Department of Health provides a routine vaccination schedule for children in the UK and are advised by the Joint Committee on Vaccination and Immunisation (JCVI). The Department of Health have announced that the meningococcal B vaccine (Bexsero) be introduced to the routine schedule as a 2+1 schedule. Cost effectiveness could also be improved by removing the current MenC conjugate vaccine dose given at 3 months of age. There is no published immunogenicity data for Bexsero when given at 2, 4 and 12 months of age (2+1 schedule) and with concomitant Infanrix/IPV/Hib which has now replaced Pediacel in the infant programme. This change to the schedule would result in three injections at 2, 4 and 12 months, and given previous reluctance among parents for three injections at one visit, an option to reduce PCV13 to a 1+1 schedule (priming dose at 3 months and booster at 12 months) will be assessed in this study.
The aim of this study is to investigate the effect of a one week high versus low glycaemic index dietary intervention on hepatic glycogen and lipid levels and blood hormone levels in a two way cross overs study and to see if there is any correlation between this and satiety or appetite.
Season of birth influences pregnancy for reasons that remain unclear however the answer may lie in the amount of sunshine pregnant women are exposed to. Sunshine, or ultraviolet light (UV) exposure is already known to have benefits for health on heart disease, strokes and depression. In pregnancy, relationships between sunshine exposure are evident in birth weight, preterm birth and risk of blood pressure complications. Vitamin D, the UV generated hormone, was thought to be responsible when low vitamin D levels were associated with these pregnancy complications. However, vitamin D replacement is ineffective at preventing these outcomes, and the investigators hypothesise that this is because it is the UV that is beneficial for pregnancy and it is working through a different pathway. A new understanding of skin function is central to this, with a 2014 study showing that exposing an adult to 20 minutes of low dose UV light lowered their blood pressure and improved blood flow. These investigators demonstrated this was a direct effect of UV on the skin and was mediated by nitric oxide, a chemical central to many aspects of pregnancy including blood pressure regulation and uterine activity. The investigators in this study have funding from Tommy's to investigate if a similar effect is seen in pregnancy on the circulation. The design is similar to the previously successful method and volunteers would be recruited from clinical areas during the second trimester. As both resting and warming for 20 minutes have the potential to have similar effects on the circulation, a control arm will expose participants to these without the UV. This pilot study would involve one visit and measurements taken would include heart rate, blood pressure, arteriography, ultrasound of the uterine arteries and blood measurements of nitric oxide levels. Arteriography is performed using a specialised arm cuff and is safe and non-invasive. A subset of these women would be invited to repeat this in the third trimester to investigate for a difference in effect at a later gestation.
Hemianopia refers to compromised vision in one half of the visual field, in either one or both eyes. Hemianopic Alexia (HA) is a reading disorder related to such impairment, usually caused by stroke or head injury. In order to read, participants have to move their eyes along a line of text three to four times per second. Such eye movements are called saccades. One makes use of peripheral visual information to the right (if reading from left to right, e.g., in English) or to the left (if reading from right to left, e.g., in Arabic) of words. HA patients are deprived of much of this information. Patients with HA require far more saccades, which slows their reading significantly and often prevents them from reading efficiently for work or pleasure. It follows that the reading ability of those who read left-to-right would be compromised more by right-sided HA, and in those who read right-to-left by a left-sided HA. This study proposes to explore the rehabilitation of left-sided HA following stroke, in Arabic readers. An online treatment package has been developed in English (http://www.readright.ucl.ac.uk/). Currently, no assessment or treatment resources exist for the condition in right-to-left readers. The aim is to develop novel Arabic reading tests and rehabilitation material. The current project proposes to 1) translate this package into Arabic, 2) develop new Arabic reading test materials and 3) collect data from Arabic reading stroke patients in a Phase 2 clinical trial. The hope is to develop an effective, novel, and empirically supported reading treatment package for Arabic readers with HA.
The purpose of this study is to determine whether ticagrelor is effective in reducing the number of days of pain, intensity of pain, and reducing the use of analgesics due to sickle cell disease
This study is looking at the feasibility of performing frailty assessments on patients with advanced hepatocellular cancer.
This study is designed to look at the effect of the geko device on the circulation in lower limbs of participants with venous leg ulcers.
The purpose of this study is to compare the overall survival of nivolumab versus chemotherapy in subjects with relapsed SCLC.
The study is aimed at answering the questions; (1) How well do the most commonly used treatments in iSGS work? and (2) What quality-of-life trade-offs are associated with each approach? With the results of this trial, the investigators hope to provide information to iSGS patients: (1) Given my personal characteristics, conditions, and preferences, what should I expect will happen to me? and (2) What are my options, and what are the potential benefits and harms of these options?
Phase II pilot randomised, factorial, short term dose escalation, open label, blinded intermediary endpoint trial, in two hospital centres in the UK, of tolerability and safety of cilostazol, isosorbide mononitrate, both or neither in patients with small vessel disease manifest as symptomatic small subcortical stroke.